HEALWELL AI's DARWEN™ Outperforms Benchmarks in Clinical Summarization and Treatment Planning

HEALWELL AI Inc, a healthcare artificial intelligence company focused on preventative care, has announced new research that demonstrates the performance and real-world impact of its DARWEN™ AI platform. The research, accepted for presentation at various scientific forums, highlights the platform's ability to outperform leading general-purpose AI models in clinical summarization and treatment-plan generation.

At the AMIA 2026 conference, HEALWELL presented findings that showed DARWEN™ AI-powered SMARTSuite outperformed benchmarks for OpenAI's GPT, DeepSeek, and Llama in clinical summarization accuracy. The research evaluated the platform using ROUGE-1, ROUGE-2, and ROUGE-L metrics, which measure the quality and accuracy of generated clinical summaries. DARWEN™ demonstrated an average 43% improvement in ROUGE-1, a 21% improvement in ROUGE-2, and a 43% improvement in ROUGE-L compared to the published benchmarks.

Separate research accepted for oral presentation at AI-MEDX 2026 showed that DARWEN™ AI had nearly 50% higher treatment-plan accuracy than a leading off-the-shelf general-purpose AI model in blinded clinician review. The study produced more clinically specific outputs, including drugs and doses, highlighting the platform's potential to enhance clinical decision-making.

In another study published in the Canadian Journal of Cardiology, HEALWELL's DARWEN™ AI-powered SMART Patient ID identified more than 4,100 patients with heart failure who were not receiving guideline-directed medical therapy. This intervention helped drive a 70% improvement in treatment optimization within six months, underscoring the platform's ability to identify patients with unmet clinical needs.

HEALWELL has secured multiple research acceptances at leading scientific forums, including EADV 2026, ACG 2026, The Menopause Society 2026, and ISPOR Europe 2026, spanning women's health, dermatology, gastroenterology, and oncology. These presentations and publications demonstrate the platform's breadth and potential impact across various therapeutic areas.

Aaron Leibtag, Head of Global Health Systems AI Strategy at HEALWELL, commented, "DARWEN™'s continued clinical and scientific validation comes as the platform gains commercial traction across health systems and life sciences. Outperforming published benchmarks for leading foundation models while demonstrating real-world patient impact validates our strategy."

Dr. Christopher Pettengell, Chief Medical Officer of HEALWELL, added, "The important question for clinical AI is not whether a model can produce an answer that sounds medically plausible. It is whether it can consistently identify the right information, preserve the clinical context, and provide the specificity required for clinicians to act. Outperforming published benchmarks for leading foundation models while demonstrating real-world patient impact validates our strategy."

The research and commercial deployments of DARWEN™ across health systems and life sciences indicate HEALWELL's progress from scientific validation to enterprise deployment and commercial scale. The company's strategy centers on translating scientific differentiation into commercial scale, with recent deployments including a multi-year deployment of DARWEN™-powered SMART Search and SMART Summary across Iowa's statewide Health Information Exchange and DARWEN™-powered clinical trial matching through WELLTRUST™'s network of more than 100,000 consented patients.